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Abstract
Background: Asthma is a difficult diagnosis to establish in preschool children. A few years ago, our group
presented a prediction rule for young children at risk for asthma in general practice. Before this prediction rule
can safely be used in practice, cross-validation is required. In addition, general practitioners face many therapeutic
management decisions in children at risk for asthma. The objectives of the study are: (1) identification of
predictors for asthma in preschool children at risk for asthma with the aim of cross-validating an earlier derived
prediction rule; (2) compare the effects of different treatment strategies in preschool children.
Design: In this prospective cohort study one to five year old children at risk of developing asthma were selected
from general practices. At risk was defined as 'visited the general practitioner with recurrent coughing (≥ 2 visits),
wheezing (≥ 1) or shortness of breath (≥ 1) in the previous 12 months'. All children in this prospective cohort
study will be followed until the age of six. For our prediction rule, demographic data, data with respect to clinical
history and additional tests (specific immunoglobulin E (IgE), fractional exhaled nitric oxide (FENO), peak
expiratory flow (PEF)) are collected. History of airway specific medication use, symptom severity and health-
related quality of life (QoL) are collected to estimate the effect of different treatment intensities (as expressed in
GINA levels) using recently developed statistical techniques. In total, 1,938 children at risk of asthma were
selected from general practice and 771 children (40%) were enrolled. At the time of writing, follow-up for all 5-
year olds and the majority of the 4-year olds is complete. The total and specific IgE measurements at baseline
were carried out by 87% of the children. Response rates to the repeated questionnaires varied from 93% at
baseline to 73% after 18 months follow-up; 89% and 87% performed PEF and FENO measurements, respectively.
Discussion: In this study a prediction rule for asthma in young children, to be used in (general) practice, will be
cross-validated. Our study will also provide more insight in the effect of treatment of asthma in preschool
children.
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Background
Asthma is the most prevalent chronic illness in children.
It is an inflammatory disorder of the airways and is
strongly associated with airway hyperresponsiveness and
symptoms like wheezing, shortness of breath, and cough-
ing [1,2]. Potential predictors for asthma in childhood or
later in life have been studied widely. Predictors that have
already been identified include environmental factors; i.e.
exposure to allergens [3-6], tobacco smoke [7,8] , respira-
tory (viral) infections [9-11], and diet (particularly breast-
feeding) [12]. But also 'non environmental' factors such as
sex [13,14] and obesity [15,16] are predictors for asthma.
It is thought that early identification of children at high
risk for asthma may improve their management resulting
in fewer respiratory symptoms, exacerbations and emer-
gency medical visits while improving their quality of life
(QoL) and preventing loss of lung function and airway
remodelling over time [17-20].
A few studies have derived prediction rules to predict
asthma later in life [21-23]. Perhaps the most well known
prediction rule (clinical asthma-risk index) was developed
in the Tucson Children's Respiratory Study by Castro-Rod-
riguez et al. [22]. This prediction rule was constructed in
preschool children from the general population with
symptoms of frequent wheezing. Although this prediction
rule is helpful to identify children at high risk of (develop-
ing) asthma later in life in the general population, it can-
not automatically be used in general practice. Factors that
determine which children will visit the general practi-
tioner (GP) are not incorporated in the Tucson prediction
rule, influencing the strength of the components in the
rule. Also a diagnosis of asthma later in life was based on
surveys which is a less objective measure compared to a
clinical outcome based on spirometry and hyperrespon-
siveness.
Therefore, Eysink et al. [23] presented a prediction rule for
general practice with factors that determine which chil-
dren will visit the GP. This prediction rule also used an
objective outcome measure of asthma at age six; i.e. a
combination of current symptoms (complaints of wheez-
ing and/or shortness of breath and/or recurrent coughing)
and/or use of β2 agonists and/or inhaled corticosteroids
during the previous 12 months in combination with air-
way hyperresponsiveness to methacholine (PC20 FEV1 ≤
8.0 mg/ml, or > 10% increase in FEV1 after rapid acting β2
agonists (salbutamol) inhalation if baseline airflow
obstruction precluded the methacholine challenge). The
Eysink prediction rule was based on age at presentation,
wheezing, family history of allergy for pollen, and specific
immunoglobulin E (IgE) to house dust mite, cat and dog
dander. Although the asthma probability varied from
1.3% to 94.5% with a bootstrapped area under the curve
(AUC) between 0.78 to 0.92, it is essential that the rule is
validated prospectively on a separate population before
use in practice [24]. Clinical prediction rules typically
demonstrate reduced performance in a new patient popu-
lation because they are optimally modeled to the original
data set. In the present study Eysink's existing prediction
rule will be cross-validated.
Although prediction of asthma in preschool children is
important with a view to prevention, the GP also faces
therapeutic management decisions in these children at
risk of developing asthma. Currently, treatment intensity
is categorized according to the international Global Initi-
ative for Asthma guidelines (GINA) [25]. However,
according to GINA, available literature on treatment of
asthma in preschool children precludes detailed treat-
ment recommendations. Moreover, randomized trials
(RCTs) in these young children in primary care are not
forthcoming. Therefore, we will determine the effect of
different treatment intensities (GINA levels) on symp-
toms and QoL in preschool children at risk for asthma in
a prospective cohort setting. In our population-based pro-
spective cohort study, we will compare the effects of no
treatment and the different GINA treatment intensity lev-
els most commonly used by Dutch GPs. The prescription
histories will shed an indirect light on treatment adher-
ence (frequency of repeat prescriptions), but the main
strength of our approach is that we learn about real-life
effects of what physicians prescribe/advise, incorporating
real-life adherence levels.
The AiRway Complaints and Asthma DEvelopment
(ARCADE) prospective cohort study has two main objec-
tives. First, we will cross-validate the prediction rule of
Eysink et al. Second, the effect of different treatment strat-
egies on symptoms and QoL in preschool children will be
compared.
This article reviews the study design and baseline data of
the children in this general practice based study.
Methods and design
The ARCADE study is an ongoing multicenter, prospective
cohort study which started in 2004 and will end in 2011,
when all enrolled children have reached the age of six
years. Additional file 1 shows the time frame of the study,
including details of the type of contacts with the study
population in the various phases of the study. The study
was approved by the Central Committee on Research
Involving Human Subjects (CCMO/P04.0098C).
Enrollment of children and time frame
In three areas in The Netherlands, one to five year old chil-
dren at risk to develop asthma were selected from 14 gen-
eral practices. Children at risk for asthma were defined as
'visited the general practitioner with recurrent coughing (≥
2 visits), wheezing (≥ 1) or shortness of breath (≥ 1) in the
previous 12 months'.BMC Pulmonary Medicine 2009, 9:13 http://www.biomedcentral.com/1471-2466/9/13
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Figure 1 shows the flow of patients through the study.
Briefly, Parents of eligible children received mailed infor-
mation (including a reply card) about the study from their
GP (stage 1). On the reply card the parent(s) could indi-
cate whether they considered participation in ARCADE. A
reminder letter was sent to parents who had not returned
the reply card, 7 days after the mailing. All parents that
indicated considering participation in the study received
detailed written information (with an informed consent
form) from the researchers (stage 2). After seven days a
reminder was sent to all parents who had not returned the
informed consent form. Subsequently, all parents who
had not responded to the reminder were approached by
telephone. Parents of children who returned a signed
informed consent form were included in ARCADE.
Validation and updating of asthma prediction rule
Sample size calculation
The final prediction rule will contain up to 5–10 variables,
taking into account practical efficiency. A widely accepted
rule is that for each variable about 10 cases are required to
prevent over-fitting of the model (Events Per Variable
rule) [26]. This implies that 100 cases of asthma are
needed to model these 10 variables. We expect the preva-
lence of asthma in the ARCADE cohort to be about 15%.
With the inclusion of 771 children in the study, we may
screen 11 variables. This prediction rule will be validated
with the existing one of Eysink et al., as is recommended
in the pertinent literature [24].
Measurements (Additional file 1)
Questionnaire background & symptoms
The parents of the children, annually, receive a question-
naire on (changes in) housing conditions, family history
of allergy, asthma and eczema, presence of pets, breast-
feeding, and asthma-related symptoms until the children
reach the age of 6. Information about wheezing, rhinitis,
eczema, cough, and phlegm is obtained by the Core Ques-
tionnaire of the International Study of Asthma and Allergy
in Children (ISAAC) [27].
Allergy
Total immunoglobulin E (total IgE) and specific immu-
noglobulin E (specific IgE) directed against house dust
mite, cat and dog dander is determined by radioaller-
gosorbent test (RAST) at baseline [22,28]. Children under
4 who tested negative at baseline will be retested at the age
of 4, to assess the predictive value of sero-conversion. A
convenient method (finger prick) for sampling blood for
analyses of total and specific IgE is used [28].
IgE positivity to house dust mite, cat and/or dog dander is
defined as > 0.35 kU/l.
Inflammatory markers
Fractional Exhaled Nitric Oxide (FENO) is measured in
the hospital or general practice at age 5 using an offline
technique. Exhaled air is collected in a NO-impermeable
Mylar balloon (ABC balloons, Zeist, The Netherlands). All
balloons are analyzed in a NO-analyzer (Aerocrine AB;
Sweden) within a time period of 6–8 hours after taking
the samples [29].
Spirometry at age 5
Peak expiratory flow (PEF) is measured twice daily over a
period of 14 days at age 5. PEF is performed on a One
Flow FVC Memo (Clement Clark International, Essex,
United Kingdom) by the children in their home environ-
ment, after a personal demonstration by a research assist-
ant. The One Flow FVC Memo measures and stores the
PEF automatically. Thus, errors due to incorrect reading
and registration are prevented [30].
Outcome (asthma at age 6)
Asthma is defined as a combination of current symptoms
(complaints of wheezing and/or shortness of breath and/
or recurrent coughing) and/or use of asthma medication
(β2 agonists and/or inhaled corticosteroids) during the
previous 12 months in combination with airway hyperre-
sponsiveness to methacholine. Airway hyperresponsive-
ness is defined as PC20 FEV1 ≤ 8.0 mg/ml, or > 10%
increase in FEV1 after rapid acting beta-2-agonists (salb-
Flowchart of children in the study Figure 1
Flowchart of children in the study. IC: Informed consent 
GP: General practitioner.
Children assessed for eligibility (n=3020) 
Parents received invitation letter (n=1938)
 Returned reply card (n=587)
Yes, consider participation (n=427)
No, do not consider participation (n=160)
Reminder letter to non-responders (n=1351)
 Returned reply card after reminder (n=644)
Yes, consider participation (n=495)
No, do not consider participation (n=149)
Parents that consider participation (n=922) 
Excluded – children did not meet inclusion 
criteria (n=1082)
T-1 – Search electronic 
medical records GP
T0 – Invitation letter, 
information + reply card, 
sent by GP
 Excluded – known temporary stay (n=1) 
Parents received information letter (n=921)
 Returned IC (n=307)
Yes, want to participate (n=258)
No, do not want to participate (n=49)
Reminder letter to non-responders (n=614)
 Returned IC within 8 days after reminder (n=255)
Yes, want to participate (n=223)
No, do not want to participate (n=32)
Phone call to non-responders (n=359)
Final participation rate (n=771/1938, 40%)
T4 – Phoned by researchers
T2 – Information letter, 
detailed information + IC, 
sent by researchers
T3 – Reminder sent by 
researchers
T1 – Reminder sent by GPBMC Pulmonary Medicine 2009, 9:13 http://www.biomedcentral.com/1471-2466/9/13
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utamol) inhalation if baseline airflow obstruction pre-
cluded a methacholine challenge [31].
Spirometry is obtained using a Pulmoassist 2 spirometer
(Jaeger, Würzburg, Germany). Bronchial responsiveness
to increasing doses of methacholine (PC20) is measured
with a gauged DeVilbiss 646 nebulizer (DeVilbiss, Somer-
set, MA, USA) with an output of 0.13 ml/min according to
the modified method of Cockroft et al. [32]. Children on
asthma-medication will withheld all bronchodilators 48
hours before the test. In case of shortness of breath chil-
dren receive ongoing rapid acting beta-2-agonists up to 8
hours before the test.
Statistical analysis prediction rule
At the time of writing, a failsafe model selection strategy
on which all statisticians and other experts in diagnostic
and predictive modeling agree does not appear to exist.
However, in his book 'Regression modeling strategies
(2001)' [33] , Harrell made some general proposals for
researchers to tailor to the specific circumstances. We
intend to use penalized logistic regression, and Tib-
shirani's  lasso  (least absolute shrinkage and selection
operator) [34] in particular to combine the requirements
of counteracting overoptimism (shrinkage of regression
coefficients) while leaving the opportunity that some
coefficients are set to zero, which serves the requirement
of a parsimonious model.
Bootstrapping will be used to estimate the penalization
coefficient [34]. As a form of sensitivity analysis, we shall
also explore Sauerbrei and Schumacher's bootstrapped
stepwise regression [35] (p-entry = 0.15; p-remove = 0.20;
predictor retained if selected in >70% of bootstrap sam-
ples; method = forward) to see how well these approaches
concur. We will avoid univariable preselection of predic-
tors. The linearity assumption will be checked for all con-
tinuous predictors. The final model will be bootstrapped.
Discrimination of the model will be visualized in high res-
olution histograms and summarized as 5th, 10th, 25th
50th, 75th, 90th, and 95th centiles of these, Brier score
and the area under the receiver operating characteristics
curve (ROC) with 95% confidence intervals (overall dis-
crimination) [36].
Using the regression coefficients of the independent diag-
nostic indicators, an easy to use, multivariable diagnostic
rule (asthma prediction rule) will be derived, consisting of
relevant tests and their diagnostic values.
Effect of different treatment intensities
Continuous registration of treatment by GP
As children reach the age of 6 and follow-up ends, the
medication prescription histories within the ARCADE
period will be read from the GPs' electronic medical
records and classified into one of the Global Initiative for
Asthma Guidelines [25] levels for treatment. As medica-
tion histories may change over time, they will be treated
as time-varying exposures.
Continuous registration of respiratory symptoms by GP
The GPs will score nine common airway symptoms (such
as symptoms of coughing, wheezing and shortness of
breath) in a standardized way 'A9-form'. These items are
scored each time a child participating in ARCADE visits
the GP with airway complaints. Registration will be car-
ried out in an electronic way (a pop-up menu).
QoL measurements
Every 6 months until the children reach the age of 6, the
parents of the children receive a (health related) QoL
questionnaire (PAQLQ/CHQ) [37,38].
Measurements of outcome
The main outcome measures are mean severity level
(number of symptoms scored as positive) and health-
related QoL. These measures will be calculated at specific
time-points (e.g. the effect at 12 months after initiation)
and longitudinally over time.
Statistical analyses medication strategies
The causal effect of interest is that of treatment strategies
(GINA classified) on complaint severity and (health-
related) QoL. However, complaint intensity and QoL act
as time-dependent confounder and intermediary factor at
the same time. Complaint intensity acts as time-depend-
ent confounder because children with more severe com-
plaints are more likely to receive more aggressive
treatment, and present complaint level may predict future
complaint intensity. It acts as intermediate variable
because the treatment they receive may change com-
plaints and thus complaints are in the intermediate path-
way to QoL. The same holds true for QoL and complaint
intensity and QoL may also influence each other. Analysis
of the treatment effect using standard methods (such as
Cox regression), adjusting for the confounding by indica-
tion by including both variables in the model will then
cause bias [39]. In particular, the indirect effect of treat-
ment through complaints will be lost by conditioning on
complaint level.
We will use more recently developed methods for causal
inference from observational data, such as marginal struc-
tural models (MSM) [40-49]. Marginal structural models
use the detailed information on each child to predict treat-
ment allocation (more severe complaints on average trig-
ger more intense treatment levels) and adjust for it
appropriately. This yields estimates of the causal effect of
treatment comparable to that obtained from a RCT,BMC Pulmonary Medicine 2009, 9:13 http://www.biomedcentral.com/1471-2466/9/13
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assuming that all important confounders are measured
and correctly adjusted for.
We plan to study the effects of fixed treatment levels as
well as the effects of dynamic treatment regimes. The latter
analysis emulates a RCT in which one treatment arm may,
for example, receive the following (dynamic) regime:
immediately step up one GINA level if complaints are not
fully controlled (as measured by our nine clinical items).
This may be compared to a regime stipulating that the
number of levels to be stepped up must depend on the
degree of non-control (partly uncontrolled – uncon-
trolled – exacerbation) [50-53].
Discussion
Results
Patient selection and participation
For the ARCADE cohort, 3020 children were selected from
14 general practices in three cities in The Netherlands
between October 2004 and July 2006 (figure 1). On aver-
age, 138 children (range 44 to 426) per practice were iden-
tified from the electronic medical records of the GPs by
using search terms related to coughing, wheezing and
shortness of breath. One researcher (KvW) verified the
computer search by checking case notes and a total of
1,938 children were defined as 'at risk' for developing
asthma and deemed suitable for ARCADE by their GP.
Reasons for non-approval included (important) comor-
bidity, known temporary stay in the region or parents
unable to read or understand Dutch or English. Of all chil-
dren, 921 parents considered participation – returned the
reply card, wanted to receive detailed information and an
informed consent (IC) form. In total 771 parents were
enrolled in the cohort study. The overall participation rate
was 40% (771/1938). The children of parents that were
enrolled in the study did not differ on age, sex and symp-
toms at onset to the children that were not enrolled (Table
1).
Compliance with the study protocol (after 18 months of follow-up)
As the assessment schedule shows (Table 2), ARCADE col-
lects data on covariates at baseline and annually using
questionnaires (e.g. ISAAC and QoL). The response rates
to these repeated questionnaires varied from 93% at base-
line to 74% after 18 months of follow-up. After 18
months of follow-up, 49 parents indicated that they did
not want to participate any longer. The reasons why par-
ents indicated to stop included lack of time, lost interest
in the study or child did not have airway complaints any-
more.
Total serum IgE and specific serum IgE, performed at base-
line, resulted in a response rate of 87%. After a follow-up
of 18 months, 131 5-year old children have been invited
Table 1: Characteristics of children enrolled in the study
Enrolled in the study (%)
(n = 771)
Not enrolled in the study (%)
(n = 1167)
Sex
Male 432 (56.0) 630 (54.0)
Female 339 (44.0) 538 (46.1)
Age at onset
1 267 (34.6) 349 (29.9)
2 220 (28.5) 343 (29.4)
3 127 (16.5) 227 (19.5)
4 121 (15.7) 203 (17.4)
5 36 (4.7) 45 (3.9)
Symptoms at onset
One respiratory symptom 518 (67.2) 897 (76.9)
Cough (2×) 420 (54.5) 763 (65.4)
Wheeze 57 (7.4) 83 (7.1)
Shortness of breath 41 (5.3) 51 (4.4)
Two respiratory symptoms 195 (25.3) 221 (18.9)
Wheeze and cough 121 (15.7) 150 (12.9)
Shortness of breath and cough 55 (7.1) 55 (4.7)
Shortness of breath and wheeze 19 (2.5) 16 (1.4)
Three respiratory symptoms 58 (7.5) 49 (4.2)
Shortness of breath, wheeze and cough 58 (7.5) 49 (4.2)
Numbers are n (percentages in parentheses)BMC Pulmonary Medicine 2009, 9:13 http://www.biomedcentral.com/1471-2466/9/13
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to perform a peak flow measurement and a FENO-meas-
urement. Data were complete for 89% and 87%, respec-
tively.
Outcome (asthma at age 6)
After 18 months of follow-up, 32 children in the ARCADE
cohort reached the age of 6, of whom seven did not have
respiratory symptoms nor used asthma medication in the
previous 12 months. These children were defined as not
having asthma. The remaining 25 children (77%) had
complaints of wheezing and/or shortness of breath and/
or recurrent coughing and/or had used asthma medica-
tion in the previous 12 months. These children were all
invited for a methacholine challenge test to confirm or
refute a diagnosis of asthma.
Discussion
The ARCADE study started two years ago and is an ongo-
ing multicenter, prospective cohort study in which a pre-
diction rule for 1 to 5 year old children at risk for
developing asthma will be constructed. Also, the effects of
frequently used 'real-world' treatment strategies on
asthma severity in young children will be estimated.
Children were eligible for ARCADE if they were at risk of
developing asthma; i.e. they visited their GP with com-
plaints of coughing, wheezing and/or shortness of breath.
We were able to select 1,938 children from the electronic
medical records of the GPs and recruited 40% of those
identified as at risk. Participation rates increased with the
number of respiratory symptoms in the previous year. In
the coming years all children will be followed until the
age of 6.
Choices of methods in our study
Validation and updating of asthma prediction rule
For the construction of the prediction rule we collect data
easy to obtain in general practice. Therefore we chose
demographic data, data with respect to clinical history
and additional tests that can easily be performed in gen-
eral practice; i.e. total and specific IgE, FENO, and PEF.
Measuring FENO using an offline technique is time con-
suming and expensive [29] however currently FENO can
be measured with the 'NIOX mino' [54] , a small device
that provides quick and easy FENO data. Other additional
tests that could be performed in young children are the
interrupter technique (Rint) and exhaled breath conden-
sate (EBC). Although, the (additional) value of these tests
is at present studied on a large scale, these measurements
cannot be performed in general practice and were there-
fore not included in our study.
Several studies have postulated that early use of inhaled
corticosteroids could prevent the onset of asthma and sug-
gest over-treatment at a young age since inhaled corticos-
teroids appears to be effective in reducing symptoms in
high-risk young children with frequent wheezing [17-20].
However, recent large RCT studies of Bisgaard et al. [55]
and Guilbert et al. [56] showed that it seemed unlikely
that early treatment prevents asthma. Therefore, we deter-
mined not to include the use of asthma medication such
as β2 agonists and inhaled corticosteroids during the study
period as a variable in our prediction rule.
Effect of different treatment intensities
We will compare the effects of no treatment and the differ-
ent GINA treatment intensity levels most commonly used
Table 2: Details of follow-up of the first 18 months of the cohort study
Number of children invited to perform 
measurement
Number of children that performed 
measurement
Questionnaire
Baseline – symptoms and QoLa 771 718 (93.1)
Follow-up at 6 months – QoLa 755 643 (85.2)
Follow-up at 12 months – symptoms and 
QoLa
707 551 (77.9)
Follow-up at 18 months – QoLa 610 450 (73.8)
Total and specific IgE measurement b 771 670 (86.9)
NO-measurements c 131 114 (87.0)
PEF-measurements d 131 117 (89.3)
Numbers are n (percentages in parentheses)
a QoL: Quality of Life measurement
b IgE: Immunoglobulin E
c NO: Nitric oxide measurement
d PEF: Peak Flow measurementBMC Pulmonary Medicine 2009, 9:13 http://www.biomedcentral.com/1471-2466/9/13
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by Dutch GPs in a prospective cohort study. Although one
might prefer a rigorous RCT, even these do not always
shed light on all aspects that are relevant for treatment
decisions. This is so because many RCTs are atypical in
several aspects: atypical patients (restrictive clinical
domain), atypical levels of compliance (good monitor-
ing), atypical quality and compliance of concomitant
treatment (strict protocols), and, finally, not all relevant
treatment strategies may be compared (companies prefer
placebo-controls over head-to-head comparisons
although the latter are often far more relevant). Our pop-
ulation-based prospective cohort study avoids all these
atypical features. We lack the safety net of randomization.
We are confident however, that important confounders
are measured reliably in our study.
Problems
During follow-up a number of parents indicated that they
did not want to participate any longer. Reasons to stop
participating in the study included lack of time, loss of
interest in the study or disappearance of airway com-
plaints. Dropping out from the study due to reasons that
affect the outcome of asthma at age six is called informa-
tive censoring and needs to be corrected for. To estimate
the effect of treatment on an outcome, the sample is
weighted to correct for informative censoring. This is done
by estimating for each individual, at each time point, the
probability of her observed censoring history given her
observed covariate history. The weights are the inverse of
these probabilities. By weighting in this manner, individ-
uals with a "rare" censoring history (for example
unhealthy, but late censoring) receive a larger weight,
whereas individuals with a more common censoring his-
tory (for example unhealthy and early censoring) are
assigned a smaller weight. Via weighting, the sample will
resemble a sample in which no informative censoring is
present.
Conclusion
The ARCADE study is an ongoing multicenter, prospective
cohort study in which an existing prediction rule for 1 to
5 year old children at risk of developing asthma, will be
validated and updated when needed. Also, the effect of
different treatment strategies in young pre-school chil-
dren, carried out by the GP, will be compared. This will
provide more insight in treatment of asthma in young
children since available literature on treatment of asthma
in pre-school children precludes detailed treatment rec-
ommendations.
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